Olanzapine in Chinese treatment-resistant patients with schizophrenia

An open-label, prospective trial

Nan Ying Chiu, Yen-Kuang Yang, Po-See Chen, Cheng Chen Chang, I-Hui Lee, Jiunn Ren Lee

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The role of olanzapine in treatment-resistant schizophrenia has still not been clearly resolved. In addressing this issue, the current report presents an open-label, prospective, 13 week trial with olanzapine use in Chinese schizophrenic patients who were resistant to more than two different classes of antipsychotics during a minimal 4 week treatment period for each antipsychotic drug at adequate dosage. Fifty-one inpatients were recruited after a cross-titration period and given 10-25 mg of olanzapine daily, without any concomitant antipsychotic medication. Patients were evaluated with the Brief Psychotic Rating Scale (BPRS), the Positive and Negative Symptoms Scale, the Clinical Global Impression Scale (CGI), the Abnormal Involuntary Movement Scale, the Simpson-Angus scale, and the Barnes Akathisia Scale. The olanzapine-treated patients showed significant improvement in both the positive and negative symptoms of schizophrenia by the end of the study. Overall, 20 of 51 (39.2%) responded to 10-25 mg of olanzapine per day as measured by the BPRS and CGI scores. Five patients dropped out due to the worsening of their psychotic symptoms, two patients discontinued owing to poor drug compliance, and the remaining patient complained of a lack of efficacy. Extrapyramidal side-effects were mild, and anticholinergic medications required has decreased. The present open study suggests that olanzapine may be effective and well-tolerated in Chinese treatment-resistant schizophrenic patients. Further double-blinded trials are needed to confirm this result.

Original languageEnglish
Pages (from-to)478-484
Number of pages7
JournalPsychiatry and Clinical Neurosciences
Volume57
Issue number5
DOIs
Publication statusPublished - 2003 Oct 1

Fingerprint

olanzapine
Schizophrenia
Antipsychotic Agents
Therapeutics
Psychomotor Agitation
Cholinergic Antagonists
Patient Compliance
Inpatients

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

@article{eb75238935914a1087e58ff44463b660,
title = "Olanzapine in Chinese treatment-resistant patients with schizophrenia: An open-label, prospective trial",
abstract = "The role of olanzapine in treatment-resistant schizophrenia has still not been clearly resolved. In addressing this issue, the current report presents an open-label, prospective, 13 week trial with olanzapine use in Chinese schizophrenic patients who were resistant to more than two different classes of antipsychotics during a minimal 4 week treatment period for each antipsychotic drug at adequate dosage. Fifty-one inpatients were recruited after a cross-titration period and given 10-25 mg of olanzapine daily, without any concomitant antipsychotic medication. Patients were evaluated with the Brief Psychotic Rating Scale (BPRS), the Positive and Negative Symptoms Scale, the Clinical Global Impression Scale (CGI), the Abnormal Involuntary Movement Scale, the Simpson-Angus scale, and the Barnes Akathisia Scale. The olanzapine-treated patients showed significant improvement in both the positive and negative symptoms of schizophrenia by the end of the study. Overall, 20 of 51 (39.2{\%}) responded to 10-25 mg of olanzapine per day as measured by the BPRS and CGI scores. Five patients dropped out due to the worsening of their psychotic symptoms, two patients discontinued owing to poor drug compliance, and the remaining patient complained of a lack of efficacy. Extrapyramidal side-effects were mild, and anticholinergic medications required has decreased. The present open study suggests that olanzapine may be effective and well-tolerated in Chinese treatment-resistant schizophrenic patients. Further double-blinded trials are needed to confirm this result.",
author = "Chiu, {Nan Ying} and Yen-Kuang Yang and Po-See Chen and Chang, {Cheng Chen} and I-Hui Lee and Lee, {Jiunn Ren}",
year = "2003",
month = "10",
day = "1",
doi = "10.1046/j.1440-1819.2003.01151.x",
language = "English",
volume = "57",
pages = "478--484",
journal = "Psychiatry and Clinical Neurosciences",
issn = "1323-1316",
publisher = "Wiley-Blackwell",
number = "5",

}

Olanzapine in Chinese treatment-resistant patients with schizophrenia : An open-label, prospective trial. / Chiu, Nan Ying; Yang, Yen-Kuang; Chen, Po-See; Chang, Cheng Chen; Lee, I-Hui; Lee, Jiunn Ren.

In: Psychiatry and Clinical Neurosciences, Vol. 57, No. 5, 01.10.2003, p. 478-484.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Olanzapine in Chinese treatment-resistant patients with schizophrenia

T2 - An open-label, prospective trial

AU - Chiu, Nan Ying

AU - Yang, Yen-Kuang

AU - Chen, Po-See

AU - Chang, Cheng Chen

AU - Lee, I-Hui

AU - Lee, Jiunn Ren

PY - 2003/10/1

Y1 - 2003/10/1

N2 - The role of olanzapine in treatment-resistant schizophrenia has still not been clearly resolved. In addressing this issue, the current report presents an open-label, prospective, 13 week trial with olanzapine use in Chinese schizophrenic patients who were resistant to more than two different classes of antipsychotics during a minimal 4 week treatment period for each antipsychotic drug at adequate dosage. Fifty-one inpatients were recruited after a cross-titration period and given 10-25 mg of olanzapine daily, without any concomitant antipsychotic medication. Patients were evaluated with the Brief Psychotic Rating Scale (BPRS), the Positive and Negative Symptoms Scale, the Clinical Global Impression Scale (CGI), the Abnormal Involuntary Movement Scale, the Simpson-Angus scale, and the Barnes Akathisia Scale. The olanzapine-treated patients showed significant improvement in both the positive and negative symptoms of schizophrenia by the end of the study. Overall, 20 of 51 (39.2%) responded to 10-25 mg of olanzapine per day as measured by the BPRS and CGI scores. Five patients dropped out due to the worsening of their psychotic symptoms, two patients discontinued owing to poor drug compliance, and the remaining patient complained of a lack of efficacy. Extrapyramidal side-effects were mild, and anticholinergic medications required has decreased. The present open study suggests that olanzapine may be effective and well-tolerated in Chinese treatment-resistant schizophrenic patients. Further double-blinded trials are needed to confirm this result.

AB - The role of olanzapine in treatment-resistant schizophrenia has still not been clearly resolved. In addressing this issue, the current report presents an open-label, prospective, 13 week trial with olanzapine use in Chinese schizophrenic patients who were resistant to more than two different classes of antipsychotics during a minimal 4 week treatment period for each antipsychotic drug at adequate dosage. Fifty-one inpatients were recruited after a cross-titration period and given 10-25 mg of olanzapine daily, without any concomitant antipsychotic medication. Patients were evaluated with the Brief Psychotic Rating Scale (BPRS), the Positive and Negative Symptoms Scale, the Clinical Global Impression Scale (CGI), the Abnormal Involuntary Movement Scale, the Simpson-Angus scale, and the Barnes Akathisia Scale. The olanzapine-treated patients showed significant improvement in both the positive and negative symptoms of schizophrenia by the end of the study. Overall, 20 of 51 (39.2%) responded to 10-25 mg of olanzapine per day as measured by the BPRS and CGI scores. Five patients dropped out due to the worsening of their psychotic symptoms, two patients discontinued owing to poor drug compliance, and the remaining patient complained of a lack of efficacy. Extrapyramidal side-effects were mild, and anticholinergic medications required has decreased. The present open study suggests that olanzapine may be effective and well-tolerated in Chinese treatment-resistant schizophrenic patients. Further double-blinded trials are needed to confirm this result.

UR - http://www.scopus.com/inward/record.url?scp=0141928114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141928114&partnerID=8YFLogxK

U2 - 10.1046/j.1440-1819.2003.01151.x

DO - 10.1046/j.1440-1819.2003.01151.x

M3 - Article

VL - 57

SP - 478

EP - 484

JO - Psychiatry and Clinical Neurosciences

JF - Psychiatry and Clinical Neurosciences

SN - 1323-1316

IS - 5

ER -